Role of Nucleic Acid–Sensing TLRs in Diverse Autoantibody Specificities and Anti-Nuclear Antibody–Producing B Cells

Yi Ting Koh, John C. Scatizzi, Jennifer D. Gahan, Brian R. Lawson, Roberto Baccala, K. Michael Pollard, Bruce A. Beutler, Argyrios N. Theofilopoulos and Dwight H. Kono

*J Immunol* 2013; 190:4982-4990; Prepublished online 15 April 2013;
doi: 10.4049/jimmunol.1202986
http://www.jimmunol.org/content/190/10/4982
Role of Nucleic Acid–Sensing TLRs in Diverse Autoantibody Specificities and Anti-Nuclear Antibody–Producing B Cells

Yi Ting Koh,* John C. Scatizzi,* Jennifer D. Gahan,* Brian R. Lawson,* Roberto Baccala,* K. Michael Pollard,‡ Bruce A. Beutler,‡ Argyrios N. Theofilopoulos,* and Dwight H. Kono*

Nucleic acid (NA)–sensing TLRs (NA-TLRs) promote the induction of anti-nuclear Abs in systemic lupus erythematosus. However, the extent to which other nonnuclear pathogenic autoantibody specificities that occur in lupus and independently in other autoimmune diseases depend on NA-TLRs, and which immune cells require NA-TLRs in systemic autoimmunity, remains to be determined. Using Unc93b1<sup>3d</sup> lupus-prone mice that lack NA-TLR signaling, we found that all pathogenic nonnuclear autoantibody specificities examined, even anti-RBC, required NA-TLRs. Furthermore, we document that NA-TLRs in B cells were required for the development of antichromatin and rheumatoid factor. These findings support a unifying NA-TLR–mediated mechanism of autoantibody production that has both pathophysiological and therapeutic implications for systemic lupus erythematosus and several other humoral-mediated autoimmune diseases. In particular, our findings suggest that targeting of NA-TLR signaling in B cells alone would be sufficient to specifically block production of a broad diversity of autoantibodies. The Journal of Immunology, 2013, 190: 4982–4990.

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by multiorgan involvement and high levels of circulating autoantibodies, most commonly to nuclear Ags. Importantly, substantial evidence supports a critical role for the endolysosome-restricted nucleic acid (NA)–sensing subset of TLRs (NA-TLRs) in the production of such anti-nuclear autoantibodies and in the pathophysiology of lupus (1). Accordingly, overexpression of the ssRNA-binding TLR7 exacerbated disease in susceptible strains and could even induce lupus in nonautoimmune mice (2–6), whereas absence of most or all NA-TLR signaling in lupus-prone mouse deficient in MyD88 (7) or Unc93b1 (3d mutation) (8) reduced most clinical manifestations and mortality. Further dissection of the NA-TLRs suggested that TLR7 and, to a lesser extent, the DNA-binding TLR9 are most critical for lupus induction (9–14). Notably, deletion of these TLRs inhibited autoantibodies to self-Ags containing their corresponding ligands: anti-ribonucleoprotein (RNP) was inhibited with TLR7 deficiency, and anti-dsDNA or chromatin was inhibited with TLR9 deficiency (7, 9, 13).

Although the relationship of NA-TLRs to nuclear and RNP autoantibodies is well documented, SLE is also associated with a wider array of autoantibodies that include specificities with less clear connections to NAs, several of which are associated with diseases that can occur independent of lupus (15, 16). These include anti–β2-gp1 (GP1) and anti-cardiolipin in the antiphospholipid syndrome, anti-myceloperoxidase (MPO) in certain vasculitides, and anti-RBCs, such as those against band 3 or glycophorin A, in autoimmune hemolytic anemia (17–19). In models of antiphospholipid syndrome and hemolytic anemia, studies have shown increased autoantibody production due to TLR7 duplication (Yaa mutation), suggesting NA-TLRs might affect most lupus autoantibody specificities (20, 21). However, it is not known to what extent non-NA–targeted autoantibodies are dependent on NA-TLRs or if they share a common production mechanism with anti-nuclear Abs (ANAs) and anti-RNP.

NA-TLRs are postulated to promote lupus by both nonspecific activation of the innate immune system and specific induction of autoreactive B cells. In the former, activation of the endosomal NA-TLRs can occur after engulfment of NA-containing immune complexes via FcYRIIa–mediated endocytosis in plasmacytoid dendritic cells (pDCs), conventional DCs (cDCs), and neutrophils (1, 22). Such activated pDCs and cDCs could potentially enhance lupus through the production of proinflammatory and immunostimulating factors, particularly type I IFNs and BAFF, and could also act as potent APCs for self-Ags, whereas activation of neutrophils has been shown in vitro to cause cell death and the release of neutrophil extracellular traps that activate pDCs (1, 22). In contrast, more specific activation of autoreactive B cells recognizing self-antigenic cargoes containing NAs is postulated to occur following receptor endocytosis and release of NAs into the endosomal compartment (1, 23). Such NA-TLR–mediated activation of self-reactive B cells has been suggested to play a role in both central and peripheral tolerance as well as amplification of autoantibody responses (1, 6, 9, 24–27). These studies provide

Copyright © 2013 by The American Association of Immunologists, Inc. 0022-1767/13/$16.00
insights into potential individual NA-TLR-dependent mechanisms, but their contribution as a whole to the pathophysiology of SLE has not been directly examined. Unc93b1<sup>3d</sup> (3d) mice have a mutation (H412R) that blocks UNC93B1-mediated trafficking of endosomal TLRs from the endoplasmic reticulum to the endosome, which abolishes endosomal TLR signaling, including all NA-TLRs (28, 29). In this study, we used 3d lupus-prone mice to determine the role of NA-TLRs in the development of nonnuclear lupus-related autoantibody specificities and cryoglobulins, the effects of complete NA-TLR deficiency on clinical manifestations, and finally the impact of cell-intrinsic NA-TLR expression on pDCs, cDCs, and B cell activation and expansion in lupus. The findings delineate specific and critical roles of NA-TLRs in autoantibody responses and broaden understanding of their significance in SLE pathogenesis.

**Materials and Methods**

**Mice**

MRL-Fas<sup>−/−</sup> Unc93b1<sup>3d</sup> (3d) and NZB-3d mice were generated by marker-assisted congeneric breeding to C57BL/6 (B6)-3d mice as previously described (30). MRL-Fas<sup>−/−</sup> and MRL-Fas<sup>−/−</sup> 3d WT (Het) mice had concordant phenotypes and were analyzed together as wild-type (WT)/Het. Data for NZB-3d mice were from female and littermate controls from N4-N7 generations except for survival, which compared N10 generation mice. NZB-3d mice were N6-N8, and littermate WT/Het controls had similar severity of autoimmune hemolytic anemia as parental NZB mice. Mice were bred at The Scripps Research Institute vivarium. Procedures were approved by The Scripps Institutional Animal Care and Use Committee.

**Pathology**

Tissues were fixed in zinc formalin solution and sections stained with periodic acid-Schiff reagent and hematoxylin. The severity of glomerulonephritis (GN) was blindly graded on a 0–4 scale as previously described (6–16). Tissues were fixed in zinc formalin solution and sections stained with periodic acid-Schiff reagent and hematoxylin. The severity of glomerulonephritis (GN) was blindly graded on a 0–4 scale as previously described (6). To assess glomerular IgG deposits, 5-µm frozen kidney sections were stained with Alexa 488 goat anti-IgG (Invitrogen) and then three to four areas per section were captured with a Zeiss Axiophot camera (Carl Zeiss) attached to a Nikon Eclipse E800 microscope (Nikon) using Axiosvision AC software and background subtracted. Exposure time was uniform for all sections, and quantification of immunofluorescence was carried out using ImageJ software (National Institutes of Health) by measuring the fluorescence intensity per area of defined glomeruli (6–16 glomeruli/mouse). Skin sections were blindly graded on a 0–4 scale for lymphocytic infiltration, basement membrane changes, and follicle loss.

**Proteinuria and serology**

Urine was collected at 24 wk and proteinuria measured using a Bio-Rad protein assay (Bio-Rad). Cryoglobulins were precipitated at 4°C for 3 d, washed five times with cold PBS, and resuspended in 0.5 M urea prior to ELISA. Serum ANAs were detected on Hep2 slides (MBL, Nagoya, Japan) with a 1:100 dilution using Alexa 488–conjugated anti-mouse IgG (Invitrogen) and scored on a 0–4 scale (8). ELISAs, performed as previously described (8), used capture and detection Abs purchased from Southern Biotechnology Associates, Jackson ImmunoResearch Laboratories, or Caltag Laboratories and Abs from Sigma-Aldrich (cardiolipin and calf thymus chromatol), Surmodics (β2-GPI and MPO), and Inova Diagnostics (Sm and RNP). Standard curves were generated using mouse reference sera (Bethyl Laboratories). For the detection of cross-reactive Abs, we used a competition ELISA (32) with 75 µg/ml chimpanzee as the competitor. IgG anti-RBCs were detected by direct Coomassie blue and flow cytometry as previously described (33).

**ELISPOT**

Splenocytes starting at 5 × 10<sup>5</sup> cells/ml were added at 2-fold serial dilutions to anti-IGG2α–coated (clone 8.3; BD Pharmingen) Multiscreen-HTS IP plates (Millipore). After 18 h at 37°C, cells were lysed, and Ab-secreting cells detected using HRP-conjugated polyclonal goat anti-IGG2α (Southern Biotechnology Associates) and 3-aminoo-ethylcarbazole substrate.

**Flow cytometry**

Isolated splenocytes were blocked with anti-CD16/CD32 and stained with combinations of dye-conjugated Abs to CD90 (G7), CD11c (N418), H2-IA (M5/114.15.2), CD19 (6D5), CD138 (281-2), CD21 (7G6), CD23 (B3B4), CD4 (GK1.5), CD3 (145–2C11), CD40 (1C10), CD93 (AA4.1), CD43 (37), IgD (11–26C.2a), IgM (RM1), B220 (RA3–6B2), Ter-119 (Ter-119), Gr-1 (RB6-8C5), CD11b (M1/70), Ly5a (A20), Ly5b (104), pDC Ag-1 (PDCA-1; ebioscience), F4/80 (BMS), CD86 (GL-1), II-4 (11B-11), IFN–γ (XMG1.2), II-17 (TC11-18H1, CD152 (PC-56), CD44 (IM-47), CD62L (MEL-14), and CD69 (H-2F3) (BD Biosciences or BioLegend). Gating strategy: CD4<sup>+</sup> T cells (CD90<sup>CD4<sup>+</sup></sup>), bone marrow B cells (CD3<sup>−</sup>Ter<sup>−</sup>Gr<sup>−1</sup> CD11b<sup>−</sup> B220<sup>−</sup>CD43<sup>−</sup> IgM<sup>−</sup> IgD<sup>−</sup>), marginal zone (MZ) B cells (CD19<sup>−</sup>CD21<sup>−</sup>CD23<sup>−</sup>, follicular (FO) B cells (CD19<sup>−</sup>CD21<sup>−</sup>CD23<sup>−</sup>), age-related B cells (CD90<sup>CD19<sup>−</sup>CD138<sup>−</sup>), plasma cells (PCs; CD19<sup>−</sup>CD138<sup>−</sup>), cDCs (CD90<sup>−</sup>CD19<sup>−</sup>CD11c<sup>PDCA-1</sup>−), and pDCs (CD90<sup>−</sup>CD19<sup>−</sup>PDCA-1<sup>−</sup>). Data were acquired on an LSRII (BD Biosciences) and analyzed by FlowJo (Tree Star).

**Bone marrow chimeras**

B6-Fas<sup>−/−</sup> or B6-Fas<sup>−/−</sup> 3d recipient mice were lethally irradiated at 1100 cGy and injected i.v. with 2 × 10<sup>6</sup> 1:1 mixed bone marrow cells with either the combination of young (<3 mo old) WT Ly5a and 3d Ly5b or WT IgH<sup>δ</sup> and 3d IgH<sup>δ</sup> donors of all B6-Fas<sup>−/−</sup> background. Mice were assessed by comparing allotopic serum Ab levels and cell populations in lymphoid organs 2–7 mo after bone marrow transfer. Differences in WT/3d stem cell ratios among individual recipients were corrected using the formula: normalized proportion (%) = 50 + (50 × (a<sub>r</sub> − a<sub>b</sub>)/b), where a<sub>r</sub> is the percent of WT or 3d in a cell population in mouse n (any individual mouse), a<sub>b</sub> is the percent of WT or 3d in the cell population in mouse n, and b is (100 − a<sub>r</sub>) if a<sub>r</sub> > a<sub>b</sub> or a<sub>b</sub> if a<sub>r</sub> < a<sub>b</sub>. Normalized proportions using a<sub>r</sub> as the mean of thymic T cell populations, double-positive populations, or splenic T cells were concordant.

**Statistical analysis**

Unpaired or paired Student t test with Welch correction if unequal variance, log rank, and Mann–Whitney U test were used to compare groups. The p values <.05 were considered significant.

**Results**

NA-TLRs are critical for some, but not all, lupus pathology in MRL-Fas<sup>−/−</sup> mice

We previously demonstrated the significance of NA-TLRs in B6-Fas<sup>−/−</sup> and BXSB mice (8). In this study, we examined the role of NA-TLRs on a wider spectrum of autoantibody specificities and additional disease manifestations by backcrossing the 3d mutation onto MRL-Fas<sup>−/−</sup> mice. Strikingly in 3d mutants, proteinuria (Fig. 1A) was significantly reduced to essentially normal levels, and GN was minimal (Fig. 1A, 1B). Only faint areas of IgG glomerular deposits were present in 3d mice compared with intense deposits in Unc93b1<sup>WT</sup> (WT/Het) littermate controls (Fig. 1C). Accordingly, absence of NA-TLR signaling dramatically prolonged survival, with all 3d mice surviving at 7 mo compared with only 8% of WT/Het controls (Fig. 1D). Thus, NA-TLRs are required for the development of GN.

In contrast, the incidence and severity of cutaneous lupus were not affected in 3d mutants, all of which developed skin disease by 7 mo with lesions similar to WT/Het MRL-Fas<sup>−/−</sup> mice (Fig. 2A, 2B); immune infiltration, disruption, or thickening of the basement membrane and follicle loss were also similar between the two groups (Fig. 2C). Consistent with this, IgA anti-desmoglein 3 (Dsg3) levels, previously reported to correlate with skin disease in MRL-Fas<sup>−/−</sup> mice (34), were not different (Fig. 2E), whereas IgG3 cryoglobulins, reported to be associated with skin disease in this model (35), were significantly reduced in 3d mice (Fig. 2F).

**Effect of NA-TLR signaling on hypergammaglobulinemia and ANAs in MRL-Fas<sup>−/−</sup> mice**

IgM concentrations were significantly lower in 3d mice compared with WT/Het littermate controls, reaching levels similar to nonautoimmune B6 mice (Fig. 3). Total IgG, although still higher than in B6 mice, was also significantly reduced in the 3d group due to lower concentrations of all IgG subclasses except for IgG1.
Absence of NA-TLR signaling did not affect IgA concentrations, and IgE was higher in 3d mice compared with WT/Het littermate controls (Fig. 3).

3d mice had significantly lower ANA scores, indicative of reduced autoantibodies to nuclear Ags (Fig. 4B). IgM and IgG autoantibodies to nuclear Ags, including chromatin, RNP, and Sm, were also uniformly reduced to the same level as B6 controls (Fig. 4C). Likewise, IgM rheumatoid factors (RFs) were almost undetectable (Fig. 4C). These findings underscore the central role of NA-TLRs in the production of autoantibodies to nuclear Ags.

Effects of NA-TLRs on diverse autoantibody specificities in MRL–Fas<sup>lpr</sup> mice

Next, to determine if NA-TLRs play a common role in Ab production in SLE and possibly other systemic autoimmune diseases, we examined the effect of NA-TLR deficiency on a wider spectrum of Ab specificities, specifically assessing responses to MPO, cardiolipin, β2-GP1, and Dsg3. Sera from MRL–Fas<sup>lpr</sup> background mice showed greatly reduced IgM and IgG autoantibodies to cardiolipin, MPO, and β2-GP1 in 3d mutants compared with the WT/Het group but, in contrast to Abs to the nuclear Ags, levels of IgM anti–β2-GP1 and all IgG autoantibodies with these specificities remained significantly higher in 3d mutants than in B6 mice (Fig. 5A). IgG anti-Dsg3, similar to IgA anti-Dsg3, was unaffected by the absence of NA-TLR signaling.

To determine the effects of NA-TLRs on anti-RBC Abs, we generated and examined autoimmune hemolytic anemia-prone NZB mice congenic for the 3d mutation. Similar to other lupus-related nonnuclear autoantibodies, IgG anti-RBC production was partially, but significantly, inhibited in the NZB mice homozygous for 3d (Fig. 5B). Thus, although >50% of NZB 3d mice were Coomb positive by 10 mo, levels of IgG anti-RBCs and splenomegaly, even among the Coomb-positive mice, remained lower than in WT mice. Taken together, our data indicate that NA-TLR–mediated induction and/or amplification of autoantibodies is a common mechanism for most specificities in lupus, but the degree of dependence on NA-TLRs varies according to specificity.

Although evidence suggests that NA-TLR–dependent autoantibodies in lupus largely develop because they can bind to NA-containing material (36), certain specificities such as anti-cardiolipin
FIGURE 3. Total isotype and subclass Ig concentrations in 3d MRL-Fas<sup>−/−</sup> mice. Ig isotype and IgG subclass levels in WT/Het and 3d MRL-Fas<sup>−/−</sup> mice and B6 controls at 6 mo (6–17 mice/group). One of three independent experiments is shown. *p < 0.05, **p < 0.01, ***p < 0.001; also not indicated in the figure, p < 0.05 for WT/Het versus B6 for all Ig isotypes and IgG subclasses except IgG2b.

FIGURE 4. ANA specificities and IgM RF in MRL-Fas<sup>−/−</sup> 3d mice. (A) Representative ANA staining (original magnification ×63) from 6-mo-old Het and 3d MRL-Fas<sup>−/−</sup> mice. (B) ANA scores for WT/Het and 3d MRL-Fas<sup>−/−</sup> mice (10–14 mice/group). (C) IgM RF and IgM anti-chromatin (top panel) and IgG anti-chromatin, IgG anti-RNP, and IgG anti-Sm (bottom panel). Each symbol represents an individual mouse. Data representative of at least two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001; p < 0.05 for WT/Het versus B6 for all autoantibodies in (C).
FIGURE 5. Nonnuclear autoantibody levels in 3d mice. (A) IgM anti-cardiolipin, –β2-GP1, and -MPO (top panel) and IgG anti-cardiolipin, –β2-GP1, -MPO, and -Dsg3 (bottom panel) in 6- to 7-mo-old WT/Het MRL-Fas<sup>−/−</sup>, 3d/MRL-Fas<sup>−/−</sup>, and B6 mice. p < 0.01 for WT/Het versus B6 for all IgM and IgG autoantibodies. (B) Anti-RBC and splenomegaly in NZB WT/Het and 3d mice. IgG direct Coomb test (n = 11–20 for WT/Het, 4–7 for 3d; p < 0.0001; left panel). Mean fluorescence intensities of IgG anti-RBCs (middle panel). Spleen weights from 10-mo-old mice (right panel). (C) Chromatin competition ELISA. Diluted sera from 6- to 7-mo-old WT/Het or 3d with IgG anti-cardiolipin, anti-MPO, or anti-chromatin specificity were added to ELISA plate wells with or without chromatin (6–17 mice/group). One of three independent experiments is shown. *p < 0.05, **p < 0.01, ***p < 0.001.

Discussion

In this study, we used the 3d mutation that selectively abolishes NA-TLR signaling to probe the specific role of NA-TLRs in lupus pathogenesis and document two main findings. First, NA-TLRs are critical for the production of all pathogenic autoantibody specificities in the MRL-Fas<sup>−/−</sup> and NZB lupus models affecting both nuclear and nonnuclear self-Ags. Second, B cell–intrinsic NA-TLR engagement is required for optimal production of autoantibodies in B6-Fas<sup>−/−</sup> mice. These and other results provide new insights into the disease-shaping role of NA-TLRs in SLE and have implications for treatment.

Although inferred from previous studies, our findings in MRL-Fas<sup>−/−</sup> and NZB mice now document that autoantibody specificities associated with autoimmune pathology, including ANAs, anti-MPO, anti–β2-GP1, anti-cardiolipin, and anti-RBCs, are highly dependent on NA-TLRs, providing direct evidence for a unifying pathogenic basis for autoantibody production in lupus and possibly other autoimmune diseases such as p-antineutrophil cytoplasmic antibody–associated vasculitides, anti–phospholipid syndrome, and autoimmune hemolytic anemia. These findings suggest that most autoantibodies associated with lupus bind to NAs or antigenic cargoes containing a sufficient amount of NAs to stimulate NA-TLRs upon endolysosome uptake (1). Indeed, MPO binds to DNA in neutrophil extracellular traps, and both cardiolipin and β2-GP1 can be detected on the surface of apoptotic cells; Dsg3, however, for which autoantibodies were not dependent on NA-TLRs, is not associated with NAs (41–44). Our findings also support the possibility that cross reactivity to nuclear material might enhance the production of some autoantibody specificities, such as anti-cardiolipin. Furthermore, because circulating RBCs have extruded both nuclei and mitochondria and therefore lack DNA, the dependence of anti-RBC on NA-TLRs implies that cellular RNA, which in RBCs includes both ribosomal and mRNA, is sufficient to activate NA-TLRs and induce autoantibodies to surface Ags that do not themselves directly bind to NAs. It is also possible that cytoplasmic membrane–associated DNA attached to the plasma membrane could contribute to NA-TLR stimulation if present in mature RBCs (45). Abs to mouse endogenous retroviral gp70 proteins are associated with the development of lupus and are dependent on NA-TLRs, specifically TLR7 (46), similar to our findings with NA–associated SLE autoantibodies. In this case, because gp70 does not bind to NAs, it was postulated that in lupus strains, the generation of replication-competent mouse polytrophic retroviruses that contain RNA might be the triggering factor for the generation of replication-competent mouse polytrophic retroviruses. In this case, because gp70 does not bind to NAs, it was postulated that in lupus strains, the generation of replication-competent mouse polytrophic retroviruses might contain RNA. The genome of TLR7 signaling, the additional deletion of TLR7 reduced anti-DNA to levels below B6.
mice, and also, to a lesser extent, other autoantibodies, including anti-histones, anti-RNA–related Ags, anti-glomerular Ags, and anti-cytochrome, to the same levels found in B6.Nba2 mice (13). These findings also support the dependence of nonnuclear autoantibody production in lupus on NA-TLRs.

Another interesting observation was that lupus autoantibodies in our study fell into three general groups based on the requirement for NA-TLRs. The first group, which primarily includes autoantibodies to nuclear Ags, was exclusively dependent on NA-TLRs with the same levels in 3d as in nonautoimmune B6 mice. Included in this category are IgM RFs, which, by recognizing Fc regions of ANAs, were previously shown to bind indirectly to NA-containing immune complexes (36). The second group, which includes autoantibodies to diverse nonnuclear targets such as MPO, RBCs, β2-GP1, and cardiolipin, was greatly amplified by NA-TLRs, but not completely dependent, as the 3d mutant MRL-\(\text{Fas}^{br}\) mice had significantly higher concentrations of these autoantibodies than B6 mice. Finally, the third group represented by anti-Dsg3 Abs were detectable at significantly higher concentrations than in

FIGURE 6. The effect of NA-TLR deficiency on immune cells in lupus mice. (A) Spleen weights and splenocyte numbers of WT/Het and 3d mice (11–19 mice/group). (B) Percentages and numbers of major spleen cell populations in MRL-\(\text{Fas}^{br}\) WT and 3d mice. (C) Percentages and numbers of spleen cell populations in MRL-\(\text{Fas}^{br}\) WT and 3d mice. (D) Percentages and numbers of CD19+CD138+ B cell subsets defined by CD21 and CD23. (E) Representative flow cytometry plots of splenic CD19+CD138+ B cell subsets defined by CD21 and CD23. (F) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (G) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (H) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (I) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (J) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (K) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (L) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (M) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (N) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (O) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (P) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (Q) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (R) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (S) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (T) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (U) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (V) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (W) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (X) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (Y) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells. (Z) Mean and numbers of IFN-γ+, IL-4+, or IL-17+ CD4+ T cells.

Lack of NA-TLRs prevented the development of significant GN in MRL-\(\text{Fas}^{br}\) mice similar to MyD88-deficient or TLR7/TLR9–double-deficient MRL-\(\text{Fas}^{br}\) mice (7). Nonetheless, we detected low levels of glomerular IgG deposits, possibly related to the residual low levels of nonnuclear autoantibodies and the presence of IgG3 cryoglobulins. Potentially, NA-TLR deficiency might prevent GN by reducing pathogenic autoantibody production and by locally impairing effector cell recruitment/activation in kidneys (1, 47).

In contrast to the reduction in GN, we detected no effect of NA-TLRs on cutaneous disease despite detailed examination of clinical and pathological features. This is similar to findings in TLR7/TLR9–double-deficient MRL-\(\text{Fas}^{br}\) mice, but contrasts with those in MyD88-deficient MRL-\(\text{Fas}^{br}\) mice, which exhibited a reduction in incidence presumably because of additional signaling pathways mediated by MyD88 (9, 48). Although previous studies have associated IgG3 cryoglobulinemia and RFs with skin disease in the MRL-\(\text{Fas}^{br}\) mice (35), our finding of unabated cutaneous disease in 3d mice despite reduced cryoglobulins and RF suggests that NA-TLR–dependent cryoglobulin specificities or cryoglobulins themselves are not required. In contrast, cutaneous lupus induced by tape stripping in (NZB × NZW)F1, which is both dependent on pDCs and associated with a persistent type I IFN signature, was curtailed by treatment with a bifunctional TLR7/9 inhibitor (49). We also found no effect of the 3d mutation on the production of IgA anti-Dsg3, consistent with the presence of skin disease. It should be mentioned that although anti-Dsg3 Abs were detectable at significantly higher concentrations than in...
Ly5a+ WT cells are shown. Mean B6-reduced incidence of ANAs, and only marginal IgM RF production. Furthermore, based on the absence of IgG2a anti-chromatin, only transient early expansions in WT cDCs were detected. WT B cell subsets preceded detectable shifts in WT pDCs, and in mixed BM chimeras in which early and sustained changes in most affected by NA-TLRs in the Faslpr model might be a consequence of epitope spreading secondary to skin inflammation rather than being pathogenic.

Our findings clearly identify B cells as the immune cell type most affected by NA-TLRs in the Faslpr model. This was shown in mixed BM chimeras in which early and sustained changes in WT B cell subsets preceded detectable shifts in WT pDCs, and only transient early expansions in WT cDCs were detected. Furthermore, based on the absence of IgG2a anti-chromatin, greatly reduced incidence of ANAs, and only marginal IgM RF production by 3d B cells in chimeric mice despite substantial production by WT B cells, we conclude that intrinsic NA-TLR engagement in B cells has a major influence on the production of autoantibodies to lupus Ags found in complex with NA material. This broad principle is supported by recent studies showing that normalization of TLR7 in B cells in a TLR7 transgenic model of lupus reduces some, but not all, RNA-associated autoantibodies (6) and the requirement of TLR9 expression in B cells for anti-chromatin autoantibodies (27). These studies, however, are limited to ANAs and, although likely, the extent to which this conclusion applies to Abs to nonnuclear Ags remains to be documented. Interestingly, in our chimeras, the effects of NA-TLR expression on B cells were already detectable at the immature B cell stage, suggesting that shaping of the autoimmune repertoire occurs even prior to full maturation. We also could estimate that a remarkably large (~20–30%) proportion of the PC population in the spleen and bone marrow were induced by NA-TLRs.

Another notable finding in the mixed bone marrow chimeras was a significant reduction in NA-TLR–expressing (WT) pDCs in the spleen, consistent with greater activation of these cells (40) and supporting recent findings demonstrating that pDCs are essential for lupus pathogenesis (50). WT cDCs were increased compared with 3d at the earliest 2 mo time point, but not at later time points despite presumably higher levels of immune complexes and previous evidence that cDCs can be activated by NA-containing immune complexes (51, 52). Moreover, we did not find significant differences in the activation profiles of WT and 3d cDCs in the mixed bone marrow chimeras, although increased activation of cDCs in WT compared with 3d MRL-Faslpr mice was detected. Taken together, this suggests a more limited role for NA-containing immune complexes in the activation of cDCs later in disease, which could be also mediated by type I and type II IFNs or by TLR2–mediated stimulation of cDCs by HMGB1-containing nucleosomes from apoptotic cells (53).

Previous models of autoantibody pathogenesis in lupus have proposed a multifaceted process that includes the initial activation of self-reactive B cells and the subsequent activation of pDCs and cDCs by immune complexes containing NAs, resulting in a self-perpetuating amplification of the autoimmune response (1). Our data support this overall scheme, but indicate the presence of NA-TLRs in B cells is necessary to drive the initial autoimmune response and to promote the activation and escape of tolerance of self-reactive B cells recognizing a broad range of NA-containing materials. We were also able to detect modest changes in cDCs and pDCs associated with intrinsic expression of NA-TLRs during the development of lupus, but not major shifts in activation, as might be anticipated. Nevertheless, deletion of CD11c+ cells, including cDCs, pDCs, Langerhan’s cells, and possibly ABC B cells, was shown to substantially reduce lymphocyte expansion and glomerulonephritis in MRL-Faslpr mice (54), indicating the importance of one or a combination of these cell types in disease progression.
pathogenesis. Further studies will be needed to determine the extent to which NA-TLR expression in these cell populations is required.

The initial characterization of the 3d mutation revealed a partial, but definite, defect in Ag presentation that might have influenced our results (28). However, we previously found that 3d did not reduce T-dependent humoral immune responses in mice immunized with NA-free adjuvant (8). Moreover, UNC93B1-deficient cell lines showed no defects in MHC class I or MHC II molecules (29) or class II Ag presentation (55), there was no defect in CD8 T cell responses in UNC93B1-deficient mice infected with murine CMV (56), and in vitro activation of CD8 T cells by WT and 3d APCs was reportedly equivalent (57). Thus, it seems unlikely that the partial reduction in Ag presentation in 3d mice is responsible for our findings. The 3d mutation also blocks trafficking of several other endosomal TLRs, including TLR8, for which the natural ligand in mice is not known (58), TLR11 and 12, which recognize profilin-like proteins from Toxoplasma gondii (59, 60), and TLR13, which recognizes bacterial tRNA (61, 62). TLR8 deficieny leads to lupus-like autoimmunity due to compensatory increased expression of TLR7 (12), and TLR11–13 do not recognize mamalian NAs and are not expressed in humans. Thus, it is unlikely that the lack of signaling from these endosomal TLRs accounts for our findings.

Finally, our report that NA-TLRs are required for all the examined autobodyse associated with lupus pathology and that NA-TLR expression in B cells is essential suggests that specific inhibition of NA-TLRs in B cells would be sufficient to treat SLE. Furthermore, combined with our previous finding of essentially normal humoral response to nonnatural Ags in NA-TLR-deficient 3d mice (8) and the fact that selective blocking of NA-TLRs in B cells would spare the innate immune system, this approach could provide a step toward more specific treatment of autoimmune disease with less compromise of the overall immune response necessary for combating pathogens and malignancy.

Acknowledgments

We thank Dr. D. Barnette (Scripps Clinic, La Jolla, CA) for analyzing skin pathology and M. Kat Ochcipienti (The Scripps Research Institute, La Jolla, CA) for editorial assistance.

Disclosures

The authors have no financial conflicts of interest.

References


